CAMBRIDGE, MA, 2020 – (IQVIA), a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry, has joined the Massachusetts Institute of Technology Center for Biomedical Innovation’s New Drug Development Paradigms (NEWDIGS) initiative as a Pioneer Site.
NEWDIGS provides its members a unique environment for open, precompetitive collaboration to develop solutions for systemwide impediments to biomedical innovation and patient care. IQVIA is the latest company to join NEWDIGS’s diverse list of global collaborators, which includes biopharmaceutical manufacturers, care providers, regulators, payers, health authorities, health technology assessment bodies, patient advocacy groups and other health care stakeholders.
As a Pioneer Site, IQVIA will partner with NEWDIGS for the rollout of the Real World Discovery Platform, a core real-world evidence generation platform of the NEWDIGS LEAPS Project. The RWDP is an infrastructure of diverse, federated real-world data sources, analytic capabilities and partnerships focused on discovering insights with potential predictive value for patient-centered decisions and outcomes.
The goal of the LEAPS Project is to design and pilot an innovation ecosystem for one disease that more quickly drives more value to patients in ways that work for all stakeholders. LEAPS — Learning Ecosystem Accelerator for Patient-centered, Sustainable innovation — is targeting rheumatoid arthritis in a pilot program.
“IQVIA is delighted to take an active role in the LEAPS program and bring our data, technology and domain expertise to help tackle some of healthcare’s most pressing problems,” said Rob Kotchie, President, Real World Solutions at IQVIA. “By working together, we can design and deploy advanced AIML into healthcare to improve systems performance and, ultimately, patient outcomes.”
LEAPS is advancing the mission of the MIT NEWDIGS consortium through a new collaborative systems approach to the planning, production and use of RWE across biopharmaceutical R&D and healthcare delivery. Success in LEAPS should lead to better patient outcomes while also reducing waste and inefficiency across the system.
Key elements of a LEAPS learning ecosystem now being prototyped for rheumatoid arthritis are expected to inform and provide a framework for accelerating efforts targeting other diseases. This unique approach to understanding treatment journeys and response predictors in rheumatoid arthritis will provide a strong foundation to enable a learning healthcare ecosystem and close the loop between evidence generation and care delivery.
“IQVIA is an exciting addition to our unique multi-stakeholder community,” said Gigi Hirsch, MD, executive director of NEWDIGS. “Their capabilities will be critical in designing, demonstrating and scaling a next-generation learning ecosystem for biomedical innovation.”
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies Human Data Science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With approximately 67,000 employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
The NEW Drug Development ParadIGmS (NEWDIGS) Initiative at MIT is an international “think and do tank” dedicated to delivering more value faster to patients in ways that work for all stakeholders. NEWDIGS designs, evaluates and initiates advancements that are too complex and cross-cutting to be addressed by a single organization or market sector. Its members include global leaders from patient advocacy, payer organizations, biopharmaceutical companies, regulatory agencies, clinical care, academic research and investment firms. For more information, visit http://newdigs.mit.edu.
MIT NEWDIGS Contact